Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.

Metal Drugs and the Anticancer Immune Response

Open access

Abstract

The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.chemrev.8b00396

Cites

1300 of 1300 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

2 retracted

Show all 1,298 references

Research works printed but not linked: 47

  1. van der Most R. G., 2005, Discovery Medicine, 5, 265
  2. Alberts B., 2015, Mol. Biol. Cell
  3. Seliger B., 1996, Exp. Hematol., 24, 1275
  4. Fink D., 1996, Cancer Res., 56, 4881
  5. Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
  6. 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
  7. Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
  8. 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
  9. Dempsey J. L., 1985, Cancer Res., 45, 2873
  10. Nio Y., 2000, Anticancer Res., 20, 3293
  11. Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
  12. Kleinerman E. S., 1980, Cancer Res., 40, 3099
  13. Lichtenstein A. K., 1986, Cancer Res., 46, 639
  14. 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
  15. Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
  16. 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
  17. Jiang J., 2006, Anticancer Res., 26, 2237
  18. Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
  19. Maeda K., 2011, Anticancer Res., 31, 4569
  20. Miller W. H., 2002, Cancer Res., 62, 3893
  21. 10.1097/CJI.0b013e3181755deb · DOI
  22. Kreuser E. D., 1992, Semin. Oncol., 19, 73
  23. Magnarin M., 2000, Anticancer Res., 20, 2939
  24. Nardon C., 2014, Anticancer Res., 34, 487
  25. Hashimoto K., 1994, J. Rheumatol., 21, 1020
  26. Yan A., 1990, J. Rheumatol., 17, 47
  27. Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
  28. 10.1371/journal.pone.0100933 · DOI
  29. Korbecki J., 2012, Acta Biochim. Polym., 59, 195
  30. 10.3109/1547691X.2014.996681 · DOI
  31. Desoize B., 2004, Anticancer Res., 24, 1529
  32. Sava G., 1985, Anticancer Res., 5, 249
  33. Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
  34. Brewer G. J., 2000, Clin. Cancer Res., 6, 1
  35. Redman B. G., 2003, Clin. Cancer Res., 9, 1666
  36. Pan Q., 2003, Mol. Cancer Res., 1, 701
  37. Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
  38. 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
  39. Eriksson M., 2009, Anticancer Res., 29, 11
  40. Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
  41. Sonis S. T., 2004, J. Support. Oncol., 2, 21
  42. 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
  43. Juhn S. K., 2001, Int. Tinnitus J., 7, 72
  44. Boussios S., 2012, Ann. Gastroenterol., 25, 106
  45. Takeyama K., 2000, Int. J. Hematol., 71, 144
  46. Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
  47. Lu J., 2017, Ochsner J., 17, 379

Cited by

See all 355

Metadata

Authors
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
Affiliations
  • Comprehensive Cancer Center Vienna (AT)
  • University of Vienna (AT)
Corresponding author
Berger, Walter
Venue
Chemical Reviews
Published
2018-11-29
Volume
119
Issue
2
Pages
1519-1624
ISSN
  • 0009-2665 (ISSN-L)
  • 1520-6890
OpenAlex
W2903051221
Cited by
355
References
1,298
Citations by year
2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Chemical Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
Funders
  • FP7 People: Marie-Curie Actions (609431)
  • Universit?t Wien
  • Medizinische Universit?t Wien
  • Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
MeSH terms
Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metal Drugs and the Anticancer Immune Response. https://app.cochat.ai/papers/10.1021/acs.chemrev.8b00396
The paper
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019). Metal Drugs and the Anticancer Immune Response. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.8b00396

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.